Ipamorelin Dosing Protocols for 2026: What Researchers Actually Use

Ipamorelin produces a clean, discrete GH pulse per injection — no meaningful cortisol or prolactin bleed, just selective GHSR-1a activation. The standard effective range is 100–300 mcg per injection, one to three times daily, with the GH response plateauing around 300 mcg per shot.[2][14]

Legal framing: ipamorelin is legal to purchase as a research compound; it is not FDA-approved for human therapeutic use, and its Phase II clinical program (postoperative ileus, Helsinn Therapeutics) was discontinued after missing its primary endpoint.[16][17]

---

Standard Research Protocols: Dose, Frequency, and Cycle Structure

Ipamorelin has a ~2-hour half-life and produces a GH peak around 40 minutes post-injection, with negligible plasma levels after 10 hours.[11]

Tier	Dose per injection	Frequency	Total daily dose
Entry	100 mcg	Once (bedtime)	100 mcg
Standard	200 mcg	Once or twice daily	200–400 mcg
Advanced	300 mcg	Twice or three times daily	600–900 mcg

Most researchers start at 100–200 mcg once nightly, fasted, 30 minutes before sleep — timing the induced GH pulse to align with the body's natural nocturnal surge, when somatostatin tone is lowest.[1][14] Cycle length runs 8–12 weeks on, 2–4 weeks off.[3][10]

For a broader comparison of secretagogue options, see ipamorelin vs. sermorelin for different research goals.

---

Reconstitution, Injection, and Evidence Limits

A 10 mg vial with 2 mL bacteriostatic water yields 5 mg/mL: 100 mcg = 2 units on a U-100 syringe, 200 mcg = 4 units, 300 mcg = 6 units. Subcutaneous injection into abdominal fat is standard; oral administration is non-viable due to GI peptidase degradation.[14] Food or insulin within 2 hours may blunt the pulse by raising somatostatin tone.[1][2]

The Helsinn Phase II trial confirmed ipamorelin at 0.03 mg/kg IV twice daily is well tolerated, but the primary GI endpoint missed significance (25.3 vs. 32.6 hours, p=0.15).[16] For body composition and recovery — the outcomes researchers most commonly target — no published controlled human trials exist.[15] Raun et al. (1998) confirmed ipamorelin raises GH without spiking ACTH or cortisol, a genuine advantage over GHRP-6 or hexarelin.[18] The downstream body-composition outcomes remain extrapolated from general GH physiology. Most community protocols report no subjective changes before weeks 3–4, with sleep quality the earliest commonly reported shift.[8][10]

For verified sourcing, Marek Health carries ipamorelin with third-party purity documentation. The peptide therapy treatment hub covers the full GH secretagogue landscape, and BPC-157 protocol and dosing covers stacking with tissue-repair peptides. Researchers can also review peptide therapy providers for additional sourcing options.

---

Frequently asked questions

What is the standard ipamorelin dose per injection for research protocols?

The standard effective dose range for ipamorelin is 100–300 mcg per injection, with the GH response plateauing at approximately 300 mcg per shot. Most researchers begin at 100–200 mcg once nightly, administered on an empty stomach 30 minutes before sleep to align the induced GH pulse with the body's natural nocturnal surge, when somatostatin tone is lowest. A two-injection protocol splits 200–300 mcg total across fasted morning and evening windows.

How long should an ipamorelin research cycle run before taking a break?

Published community protocols recommend running ipamorelin for 8–12 weeks on, followed by a 2–4 week rest period, with some guides extending the active phase to 16 weeks before a break. Some researchers also use a "5 days on, 2 days off" weekly pattern to limit receptor desensitization, though no controlled data confirm this approach offers an advantage over continuous daily dosing.

Does ipamorelin have clinical trial evidence supporting body composition results?

There are no published controlled human trials supporting ipamorelin's commonly targeted outcomes of body composition improvement, enhanced recovery, or sleep quality. The only Phase II human trial, conducted by Helsinn Therapeutics for postoperative ileus, missed its primary endpoint (25.3 vs. 32.6 hours, p=0.15) and was discontinued, though the compound was well tolerated at 0.03 mg/kg IV twice daily. Raun et al.'s foundational 1998 selectivity data confirmed ipamorelin raises GH without spiking ACTH or cortisol — a genuine pharmacologic advantage — but downstream body-composition outcomes remain extrapolated from general GH physiology rather than ipamorelin-specific trial evidence.